India, June 29 -- INmune Bio Inc. (INMB) is scheduled to host a conference call on Monday, June 30, 2025, beginning at 8:00 am EDT to present top-line data from its phase II trial, dubbed MINDFuL.
MINDFuL is a phase II trial investigating XPro in patients with mild cognitive impairment or Alzheimer's disease with brain inflammation. In this study, XPro is compared to a placebo to determine its impact on memory, daily functioning, and behaviour. In addition, the trial assesses the safety and tolerability of XPro.
XPro, given as a once-a-week subcutaneous injection, is a next-generation inhibitor of tumor necrosis factor (TNF).
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
A total of 208 participants...